Liezl Gambe - Author on Grafa

The Albanese government secured a key win as the Greens agree to pass the Division 296 super tax, targeting balances over $3 million.

The Bitcoin network has produced its 20 millionth coin, leaving just one million BTC remaining before the digital asset reaches its fixed supply cap of 21 million.

IMF Chief Kristalina Georgieva warned of a "new normal" for the global economy, urging policymakers to prepare for "unthinkable" shocks as Middle East conflict threatens markets and inflation.

Hewlett Packard Enterprise (NYSE:HPE) reported third-quarter financial results that showcased a significant acceleration in top-line growth, fueled by robust demand for its "as-a-service" offerings and high-performance computing.

Boundless Bio (NASDAQ:BOLD) reported a narrowed net loss for the full year 2025 and a strategic realignment of its oncology pipeline, prioritizing a novel kinesin degrader as it prepares to enter the next phase of clinical development.

Genius Group (NYSE:GNS), an education technology company focused on entrepreneurial education and business incubation, on Monday reported audited financial results for the full year ended December 31, 2025, alongside a business update highlighting its reorganization and improving operational trajectory.

ZIM Integrated Shipping Services (NYSE:ZIM) reported fourth-quarter earnings on Monday that signaled a recovery in the global container market, bolstered by a strategic shift toward more fuel-efficient vessels.

Spruce Biosciences (NASDAQ:SPRB) reported a significant reduction in annual operating expenses for 2025 on Monday, as the company successfully transitioned its clinical focus toward its enzyme replacement therapy for rare neurological disorders.

ARS Pharmaceuticals reported its 2025 financial results on Monday, highlighting the successful U.S. commercial launch of neffy, the first needle-free epinephrine nasal spray, which now anchors the company’s path toward cash-flow break-even.

HUTCHMED initiated a full market recall of the oncology drug Tazverik across Greater China on Monday, following a global withdrawal by partner Ipsen due to emerging safety data linking the therapy to secondary blood cancers.